Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

The UK Medicines and Healthcare products Regulatory Agency previously confirmed the asset’s safety and efficacy.

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

The drug helped patients live significantly longer without their cancer progressing, compared with patients who were treated ...

A quantitative continuous score identified patients with a TROP2 biomarker likely to respond to the antibody-drug conjugate, a study presented at WCLC showed.

Merck & Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. | Merck & ...

(RTTNews) - Merck & Co., Inc. (MRK) and Daiichi Sankyo (DSKYF.PK) announced that an interim analysis of the dose-optimization phase of the ongoing IDeate-Lung01 Phase 2 trial shows ifinatamab ...

Bert Coffee Jr., 64, passed away due to natural causes at his residence Saturday, August 31, 2024. Wake services began at 3:00 p.m. Monday, September 2, 2024, and continued until his funeral service, ...

On Wednesday, Jefferies, a global investment banking firm, updated its outlook on shares of Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY), raising the price target to JPY7,600 from JPY6,600.